Europe's donor-screening rule changes in 2027. The lab work starts now

A donated unit of blood and a donated cornea do not travel through the same clinical system. Reproductive cells have another route again. Yet all three can carry the same public-health question: how should services screen donors for hepatitis B and hepatitis C before human material is used in care?

Europe is moving towards a more consistent answer. On 28 July, the European Centre for Disease Prevention and Control published two surveys describing how participating EU and European Economic Area countries tested blood, tissues and cells before ECDC issued new technical guidelines in June. The results are not a warning that donations are suddenly unsafe. They are a baseline for a regulatory handover that reaches most of its legal effect in August 2027.

That timing matters. The surveys looked back at national practices reported in 2024, then set those practices beside guidelines published on 1 June 2026. They show where testing was already common and where the details still varied. In other words, this is a change-management story inside laboratories and donation services, not a new test for readers to seek out.

The hepatitis B survey found the clearest variation. Among participating countries, a nucleic acid amplification test, which looks for hepatitis B virus DNA, was mandatory or recommended for 88 percent of blood donors, 58 percent of tissue and non-reproductive cell donors, and 37 percent of reproductive cell donors. About half of responding countries required or recommended testing individual blood donations with that method. Fewer than half reported a required limit of detection.

The hepatitis C picture was more even, but not identical. A test for hepatitis C virus RNA was mandatory or recommended in 96 percent of participating countries for blood donations, 58 percent for tissues and non-reproductive cells, and 50 percent for reproductive cells. Again, 52 percent reported testing individual blood donations, while fewer than half reported a required detection limit. ECDC described the hepatitis C landscape as showing limited heterogeneity, compared with considerable heterogeneity for hepatitis B.

Those percentages need their denominators. The number of responding countries ranged from 19 to 25 across the hepatitis B fields, and from 18 to 25 for hepatitis C. They describe the participating countries, not every donation centre in Europe and not the performance of one laboratory. The surveys also captured policies and recommendations, rather than measuring every test as it happened.

The new guidelines are broader than blood. ECDC divides substances of human origin into blood and blood components, tissues and non-reproductive cells, and reproductive cells and tissues. That includes materials used in transfusion, transplantation and medically assisted reproduction. Solid organs sit outside the new EU regulation, while breast milk, faecal microbiota and plasma collected for industrial manufacturing are outside this first iteration of the hepatitis guidance.

For the services covered, the guidelines set minimum safety requirements and recommendations for donor assessment, laboratory methods and testing strategies. Countries can use stricter measures. ECDC says the updated approach is intended to catch risks that older regimes might miss, including very early acute hepatitis C infection and occult hepatitis B infection. That is a claim about the design of a screening system, not a promise that any test removes all risk.

The legal architecture is also deliberately staged. Regulation (EU) 2024/1938 will replace the older blood and tissues-and-cells directives when most provisions apply in August 2027. The regulation gives ECDC the role of developing current technical guidance on communicable-disease risks. Publishing the laboratory documents early gives national authorities and establishments time to compare methods, revise procedures, validate workflows and train staff before the handover.

WHO's global blood-safety guidance explains why consistency matters beyond this European transition. It recommends screening all blood donations for HIV, hepatitis B, hepatitis C and syphilis within a quality system. Its June 2026 fact sheet says 10 reporting countries still could not screen every donation for one or more of those infections, and only 63 percent of blood-screening laboratories globally participated in external quality-assessment schemes. Those global figures should not be read as a description of Europe. They show that the existence of a test is only one layer of safety; organisation, quality assurance and consistent standards matter too.

For patients and donors, the most important restraint is not to turn a system update into a personal result. The surveys do not say whether a particular donation is suitable, interpret anyone's hepatitis status or change individual eligibility today. Donation services apply local rules, and a reactive screening result requires the service's own confirmatory and clinical pathway. A news article cannot provide that assessment.

The useful image is therefore not a dramatic virus or a worried patient. It is a handover bench: different donated materials arriving through different routes, then meeting a common safety standard. The July surveys have made the starting point visible. The next evidence will be whether implementation narrows the differences after the 2027 rule change, without confusing uniform minimums with identical health systems.